Company intelligence / Profile preview

Calcilytix

San Francisco, California, USAgenomemedical.com ↗

Ownership: Private
Employees: ~15
Development stage: Phase 2

Overview

Calcilytix Therapeutics is conducting clinical trials for encaleret, a small molecule antagonist of the CaSR, primarily targeting ADH1 and hypercalciuric hypocalcemia. Currently, there are no approved therapies for ADH1, and conventional treatments often lead to complications like kidney stones.

Therapeutic areas: Endocrinology
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

1 asset

encaleret

Phase 2

Indications: Autosomal dominant hypocalcemia type 1, Hypocalcemia

Partnerships

Genome Medical for genetic counseling and testing services

Beyond the preview

Go deeper on Calcilytix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Calcilytix.

Explore the full profile